Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose IL-2 for GVHD Prophylaxis After Haploidentical Transplantation
NCT02659657Phase 2Unknown
- Sponsor
- Peking University People's Hospital
- Start
- Mar 2015
- Primary completion
- Jun 2021
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of aldesleukin in graft-versus-host disease (GVHD), sponsored by Peking University People's Hospital. Status: unknown.
02
Drugs
aldesleukin
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT02659657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02659657.